7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.

7 Hills Pharma has been awarded a $4.7 million CPRIT grant to advance 7HP935, a first-in-class small molecule gene therapy that enhances hematopoietic stem cell transplantation (HSCT). This therapy aims to improve stem cell engraftment and reduce infection risks, offering a better treatment option for cancer and genetic disorder patients, especially those from ethnic minorities with limited stem cell donor matches.

7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.

7 Hills Pharma announces the expansion of its patent portfolio with new claims covering innovative integrin agonist combination therapies. The newly issued patent no. 11,311,619 strengthens 7HP’s leadership in leveraging integrin activation to overcome immunotherapy resistance, expanding applications across diverse therapeutic areas.

7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.

7 Hills Pharma announces the successful completion of a Phase I clinical trial for 7HP349, an oral immunostimulant that enhances immuno-oncology drugs, COVID-19, and influenza vaccines. The study demonstrated excellent safety, tolerability, and pharmacokinetics, paving the way for Phase II clinical trials in solid tumors and vaccination for immunocompromised populations.

7 Hills Pharma appoints Michael S. Perry, CEO of AVITA Medical, as its first Chairman of the Board of Managers. The company is advancing small molecule integrin activators, including 7HP349, to enhance immuno-oncology drugs and vaccines for COVID-19, influenza, and cancer treatments.

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.